These findings establish the tRF-24-CELF1-BIN1/BECN1 axis as a key regulator of ESCC progression and the therapeutic potential of targeting this specific tRF molecule was confirmed in xenograft models, where treatment with antagotRF-24 reduced subcutaneous tumor volume compared to controls. This evidence concerns the gene BECN1 and esophageal squamous cell carcinoma.